This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Sharon Flank
Advertisement
Sharon Flank, PhD, [email protected], is CEO at InfraTrac.
Articles by Sharon Flank
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
PharmTech Weekly Roundup—June 19, 2026
4
Is Compliant AI in Pharma Even Possible? The Search for an Honest Answer
5